ArticleJournal of clinical microbiology2004
Phenotypic and molecular detection of CTX-M-beta-lactamases produced by Escherichia coli and Klebsiella spp.
Article in Journal of clinical microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 298 citations in OpenAlex.
- Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.BMC infectious diseases · 2017Trial
- Distribution and characteristics of ceftiofur-resistant Escherichia coli throughout the broiler production chain in Korea.Veterinary research · 2026Article
- ESBL-producing and virulent enteric bacteria from goats in Northeastern Brazil.Veterinary research communications · 2026Article
- Wild Fishes as Reservoirs of Gut Bacteria Carrying Antimicrobial Resistance Encoding Genes in Chilean Bays.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Detecting antibiotic resistance: classical, molecular, advanced bioengineering, and AI-enhanced approaches.Frontiers in microbiology · 2025Review
- CTX-M-ProducingInfection and drug resistance · 2025Review
- Molecular characterization of Escherichia coli producing extended-spectrum β-lactamase CTX-M-14 and CTX-M-28 in Mexico.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Analyses of Extended-Spectrum-β-Lactamase, Metallo-β-Lactamase, and AmpC-β-Lactamase Producing Enterobacteriaceae from the Dairy Value Chain in India.Antibiotics (Basel, Switzerland) · 2023Article
- Escherichia ruysiae May Serve as a Reservoir of Antibiotic Resistance Genes across Multiple Settings and Regions.Microbiology spectrum · 2023Article
- Comparative Genetic Characterization of CTX-M-ProducingMicroorganisms · 2023Article
- Prevalence and Risk Factors Associated with Multidrug Resistance and Extended-SpectrumAntibiotics (Basel, Switzerland) · 2023Article
- Detection ofFrontiers in microbiology · 2023Article
- Understanding the genetic basis of the incompatibility of IncK1 and IncK2 plasmids.Open research Europe · 2023Article
- Extended-Spectrum Beta-Lactamases ProducingAntibiotics (Basel, Switzerland) · 2022Review
- Genetic Diversity, Biofilm Formation, and Antibiotic Resistance ofVeterinary sciences · 2022Article
- Molecular characteristics of ESBL-producingJournal of veterinary science · 2022Article
- Characterization of UropathogenicMicroorganisms · 2022Article
- Abundance of colistin-resistant Escherichia coli harbouring mcr-1 and extended-spectrum β-lactamase-producing E. coli co-harbouring blaArchives of microbiology · 2022Article
- Prevalence of Multidrug-Resistant CTX-M Extended Spectrum Beta-Lactamase-ProducingFrontiers in veterinary science · 2022Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organisms producing CTX-M-beta-lactamases are emerging around the world as a source of resistance to oxyiminocephalosporins such as cefotaxime (CTX). However, the laboratory detection of these strains is not well defined. In this study, a molecular detection assay for the identification of CTX-M-beta-lactamase genes was developed and used to investigate the prevalence of these enzymes among clinical isolates of Escherichia coli and Klebsiella species in the Calgary Health Region during 2000 to 2002. In addition, National Committee for Clinical Laboratory Standards (NCCLS) recommendations were evaluated for the ability to detect isolates with CTX-M extended-spectrum beta-lactamases (ESBLs). The PCR assay consisted of four primer sets and demonstrated 100% specificity and sensitivity for detecting different groups of CTX-M-beta-lactamases in control strains producing well-characterized ESBLs. Using these primer sets, 175 clinical strains producing ESBLs were examined for the presence of CTX-M enzymes; 24 (14%) were positive for bla(CTX-M-1-like) genes, 95 (54%) were positive for bla(CTX-M-14-like) genes, and the remaining 56 (32%) were negative for bla(CTX-M) genes. Following the NCCLS recommendations for ESBL testing, all of the control and clinical strains were detected when screened with cefpodoxime and when both cefotaxime and ceftazidime with clavulanate were used as confirmation tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.